Arcutis Biotherapeutics, Inc. (ARQT)

9.23 -0.22 (-2.28%) 市場開市。 截至 10:04AM EDT。

Arcutis Biotherapeutics, Inc.

3027 Townsgate Road
Suite 300
Westlake Village, CA 91361
United States
805 418 5006
https://www.arcutis.com

版塊: Healthcare
行業: Biotechnology
全職員工: 296

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Todd Franklin Watanabe M.A.	President, CEO & Director	1.01M	271.89k	1968
Dr. Bhaskar Chaudhuri Ph.D.	Co-Founder & Independent Director	59.67k	無	1955
Mr. Masaru Matsuda Esq., J.D.	Senior VP, General Counsel & Corporate Secretary	626.22k	無	1971
Dr. Patrick E. Burnett M.D., Ph.D.	Senior VP & Chief Medical Officer	689.95k	無	1972
Mr. Rajvir Madan	Chief Digital & Technology Officer	無	無	無
Ms. Latha Vairavan	Vice President of Finance & Investor Relations	無	無	無
Ms. Courtney Barton	VP and Chief Compliance Officer & Privacy Officer	無	無	1983
Ms. Amanda Sheldon	Head of Corporate Communications	無	無	無
Ms. Ayisha Jeter	Head of Marketing & Market Access	無	無	無
Mr. Kent Taylor	Vice President of Sales	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

公司管治

截至 2024年4月1日 止，Arcutis Biotherapeutics, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：6；董事會：5；股東權利：3；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。